Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Announces plan to repurchase up to 3 mil. shares of common stock, or 5.1% of its 58.5 mil. outstanding shares, following a recent stock slide to 53-1/4 on April 8; the April 8 stock close, a 52 week low for the issue, represents a 44.1% decline since the beginning of the year, when Medtronic traded at 95-1/4. The Minneapolis-based company already has repurchased 1.5 mil. shares since the beginning of its fiscal year (May 1, 1992) under previous buy-back authorizations. The company notes in an April 9 release announcing the repurchase program that it expects "solid growth" in sales and earnings per share for both the fourth quarter and the full year.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000504

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel